GlassScriptPhysician profile
Travis James Weiss
NPI 1699084814
$4,740.70
in general payments reported to CMS, 2019-2025
36 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,475 · 2022: $397 · 2023: $929 · 2024: $899 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,850 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,850.03 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.24 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $612.51 | 2021-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.71 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $496.74 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $280.88 | 2021-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $227.40 | 2021-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $183.97 | 2021-2025 | Capvaxive, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.96 | 2021-2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $153.84 | 2021-2023 | Seglentis, Livalo |
| Novartis Pharmaceuticals Corporation | $149.72 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $143.26 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $100.55 | 2022-2024 | Auvelity |
| Astellas Pharma US INC | $89.85 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.46 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.33 | 2021-2024 | Trintellix |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $81.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $63.23 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $61.00 | 2021-2024 | Yupelri |
| Viatris Specialty LLC | $50.50 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $45.55 | 2022-2023 | Gvoke Hypopen |
| Lundbeck LLC | $39.36 | 2025 | Rexulti |
| Amarin Pharma, INC. | $38.26 | 2021-2022 | |
| Exact Sciences Corporation | $34.64 | 2023-2024 | Cologuard Collection Kit |
| Seqirus USA INC | $31.88 | 2024 | Fluad, Flucelvax |
| Ironwood Pharmaceuticals, INC | $25.21 | 2021 | |
| Dexcom, INC. | $23.20 | 2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $20.92 | 2021 | |
| Daiichi Sankyo INC. | $19.66 | 2021 | |
| Verona Pharma, INC. | $19.45 | 2025 | Ohtuvayre |
| Ardelyx, INC. | $16.06 | 2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.01 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $14.85 | 2024 | Trelegy Ellipta |
| Genzyme Corporation | $14.50 | 2024 | |
| Pfizer INC. | $14.01 | 2021 | |
| Apria Healthcare LLC | $13.41 | 2021 | |
| Medicure Pharma INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.